BIOMAT Database Logo BIOMAT Database Logo

Osteopontin as a marker of weight loss in lung cancer. 2011

Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Department of Chest Diseases, School of Medicine, Adnan Menderes University, Aydin, Turkey. fisunkaradag@yahoo.com

Although the role of osteopontin (OPN) in tumorigenesis and invasiveness is well-known, its role in systemic consequences of lung cancer has not been studied yet. The objective of the current study was to assess the value of osteopontin as a marker of weight loss in relation to systemic inflammation in non-small cell lung cancer (NSCLC) patients. A total of 63 male NSCLC patients (stage III and IV) and 25 age and sex-matched controls were included. The NSCLC patients were further divided into subgroups depending on whether they had > 5% weight loss in the last 6 months or not. Serum OPN and TNF-α concentrations were measured by ELISA using commercially available kits. Serum C-reactive protein (CRP) concentration was measured by the turbidimetric method. OPN (p = 0.001) and CRP (p < 0.001) concentrations were significantly higher in lung cancer patients compared to controls whereas TNF-α concentrations were similar in cancer and control groups (p = 0.063). There were 33 NSCLC patients (52.4%) with weight loss. Serum OPN concentration was found to be higher in this weight-losing group (p = 0.042). CRP concentration was also higher in the weight-losing group but the difference was not statistically significant (p = 0.246). TNF-α concentrations were similar in both subgroups (p = 0.094). In correlation tests, there was a positive correlation between OPN and CRP (r = 0.299, p = 0.044), but no correlation was detected between OPN and TNF-α (r = − 0.009, p = 0.930). A negative correlation was detected between OPN and BMI (r = − 0.246, p = 0.048). In addition to being an indicator of systemic inflammation in lung cancer patients, osteopontin may also be an indicator of weight loss.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Osteopontin as a Tumor Marker in Ovarian Cancer.
January 2022, Journal of mid-life health,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Categorical meta-analysis of Osteopontin as a clinical cancer marker.
February 2011, Oncology reports,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Osteopontin identified as colon cancer tumor progression marker.
January 2003, Comptes rendus biologies,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
June 2016, Cancer biomarkers : section A of Disease markers,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Weight Loss as an Untapped Early Detection Marker in Pancreatic and Periampullary Cancer.
October 2021, Annals of surgical oncology,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
[Dermatomyositis as a marker of lung cancer].
April 2009, Ugeskrift for laeger,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Comment on: osteopontin as toxic marker.
February 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Osteopontin as a molecular prognostic marker for melanoma.
January 2008, Cancer,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer.
February 2018, Journal of cachexia, sarcopenia and muscle,
Fisun Karadag, and Sule T Gulen, and Aslihan B Karul, and Naciye Kilicarslan, and Emel Ceylan, and Nilgun K Kuman, and Orhan Cildag
[Recognizing and understanding illnesses: weight loss as primary marker].
October 2007, Pflege Zeitschrift,
Copied contents to your clipboard!